The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
about
Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityRecent advance in antigen-specific immunotherapy for acute myeloid leukemiaTargeting the innate immune system as immunotherapy for acute myeloid leukemiaPredicting response to epigenetic therapyGenome-wide demethylation by 5-aza-2'-deoxycytidine alters the cell fate of stem/progenitor cells.Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionNYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.Augmenting antitumor immune responses with epigenetic modifying agents.Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AMLHypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies.Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and KillingAntineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder CancerHypomethylating agents after allogeneic blood stem cell transplantation.Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromesInducible expression of cancer-testis antigens in human prostate cancer.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Immunotherapy of cancer: reprogramming tumor-immune crosstalk.Current strategies in immunotherapy for acute myeloid leukemia.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.Epigenetics: A primer for clinicians.Opportunities and challenges for TCR mimic antibodies in cancer therapyT-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Hypomethylating Agents as a Therapy for AML.Cancer testis antigen and immunotherapy.Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.Epigenetic drug discovery: breaking through the immune barrier.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
P2860
Q26797280-AC701297-D113-4391-BBB2-47D42A2035D7Q27005765-60483E75-4AD2-41BF-A97F-1218C0CA0EA6Q27015876-1AF01EF2-AA80-4799-A25A-14FF9671C1CBQ27027751-93AC375E-7650-4198-B10F-6B8DBA5B595EQ30392550-23B43A0C-FB55-45BF-A362-22D7CC9CF4C9Q33416734-1AA8318A-F29D-4C55-B71F-19EBA6FA23D8Q33931434-1FBEBB75-42F3-4C0E-8E40-2BB9AB694D92Q34182308-FCF50FB5-17DE-4B64-AA91-54696F4805A4Q34960346-50F57FFE-580B-447F-8582-8DE1553549C7Q35048054-74BECD63-EB53-4083-954E-999C565A9AD0Q35556061-229B1C46-B2C3-401A-B021-B537C894F920Q35589288-E6C7784A-A670-49FB-B1B6-D98F769B5643Q35651714-D162989C-8AA6-4343-AF55-B4DAFE717B5DQ35832463-F5C71F06-8A7E-449F-97B3-584BA3A3014FQ35897592-4821D390-248C-467A-BE92-1B2FADE4233FQ36118290-469DC90C-06CC-41F0-BC90-C2BB8F2F4D4DQ36345656-8D955A38-7074-4CE6-A9FE-9A0A0D4DC2F9Q37022306-CADEFA32-C838-440F-B4DB-884D0FEF3177Q37290684-D6415ADE-060D-4B94-BAB0-66AA8F8B798EQ37531039-D7C09677-46A4-4862-8B08-E78916433C7CQ37685237-210B86B8-CEA0-43E9-A50B-87F9C7D25139Q37686238-50A2186C-9F9F-4F60-9E8C-B61E8EB051A3Q37731703-1561DAEE-C09B-4374-AB02-EC4CA5C9DF7AQ38055479-E8269E9B-786D-459C-90A6-704A36B08EADQ38068967-660E51D0-3F1C-41F3-9F97-FDCB56FE4DCBQ38110935-FC8AC567-0BA2-4C53-B05B-0087E1135C29Q38314204-DB0D917F-327E-4882-BE18-5A3F400D2562Q38570399-C53AE235-02C0-49BC-8892-4EEACD4B6958Q38626158-BC9C048D-2E11-4E19-88D4-9F842607F9FCQ38664735-0FCD32EC-CC9D-4CBA-94BA-387451F13C65Q38742600-C6AA59B4-F155-4D31-9A83-1F2B46D3D22FQ38770916-DEF31CF8-8DD6-4EB3-988F-E1EF287CF219Q38812269-42163341-7D92-4A6B-B0D1-C97081A6DFD0Q38873974-8A3C03E3-9D4A-4837-9A6D-AFD65F95B551Q38911864-DCFA5FB4-73C9-43CB-ACB8-0512EAB448F4Q38912232-14FACB4A-75F4-43DB-A630-1B0B24DB622AQ38952962-A961BEB8-E9EF-4893-ACCB-68067B0E9F31Q38986705-2A1C753E-CE78-4D1D-B3CC-1B29E521C96BQ38988078-F275F128-5BE1-4F3B-AB17-06199A1DF808Q39478326-978625F2-FE5A-46E0-97C2-2276650B26FA
P2860
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@en
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@nl
type
label
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@en
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@nl
prefLabel
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@en
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@nl
P2093
P1433
P1476
The DNA demethylating agent 5- ...... ens in myeloid leukemia cells.
@en
P2093
Dietmar Pfeifer
Elke Jäger
Jesús Duque-Afonso
Julia Karbach
Maika Almstedt
Michael Lübbert
Nadja Blagitko-Dorfs
P304
P356
10.1016/J.LEUKRES.2010.02.004
P577
2010-04-10T00:00:00Z